Expert Interview
Discussing the current treatment landscape for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) and the potential of Zanubrutinib(BRUKINSA®) and the phase 3 ALPINE trial.
Ticker(s): BGNE, AZN, ABBVInstitution: Paul Unger Consulting VT
- Clinical Oncologist in practice for 30 years
- Clincal Associate Professor of Medicine at the University of Vermont School of Medicine
- manages treatment for roughly 10-20 patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
